Drug Trial Radar · NCT07134335
UBT251 Injection Phase II Clinical Study (CKD)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 1, 2025
Primary completion
Jul 11, 2030
Study completion Jul 11, 2030
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
Conditions
- Obesity &Amp; Overweight
- Chronic Kidney Disease
Interventions
UBT251Drug
Subcutaneous injection once weekly
UBT251Drug
Subcutaneous injection once weekly
UBT251Drug
Subcutaneous injection once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- log-transformed urinary albumin:creatinine ratio(UACR)Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.